OKYO

OKYO Pharma Ltd

Healthcare Biological Products, (No Diagnostic Substances) Market cap: $73.5M All insider activity → Quote and statistics → Sign in to watch OKYO Sign in to set a price alert

AI summary Cluster open-market purchases by multiple OKYO Pharma directors and executives.

Insider Score Band 60–79

Research score: 62
AI adjustment: +5

Research score, not a recommendation.

Total bought$136.0K7 Form 4 purchases

Distinct insiders6open-market buyers

Lead insiderDempsey Robert JohnCEO

Cluster window2026-07-20 → 2026-07-27active

Market data

Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.

–

Why this score

Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.

Breadth number & diversity of participating insiders

100%

Seniority executive rank of buyers (CEO/CFO/Director)

88%

Commitment purchase size relative to company & holdings

71%

Context buying into stock weakness signals conviction

100%

Timing coordinated purchases within a tight window

99%

Routine-purchase discount × 1.00

Company-type / offering discount × 1.00

Net insider selling penalty − 0

Why are they buying?

AI · discretionary · catalyst none · documented

Insiders made discretionary open-market purchases of common stock without an explicit stated company catalyst in the filings.

Purchases were executed by the Chairman, CEO, and multiple other executives and directors across several consecutive days in late July 2026.

Filing references and sources

Stock Price & Insider Purchase History

Daily close price with open-market insider purchases plotted over time

Loading price history…

Transactions

7 Form 4 trades · 6 insiders Sign in to download CSV

Purchases in this cluster, grouped by insider, largest first
Date	Insider	Role	Shares	Price	Value	Filing
2026-07-20 → 2026-07-21	CERRONE GABRIELE M 4 purchases with a 63-day result · median -33.0%	Director	47,500	$1.42 avg	$67.6K
2026-07-20	CERRONE GABRIELE M		25,000	$1.40	$35.0K	SEC filing for CERRONE GABRIELE M (opens in a new tab)
2026-07-21	CERRONE GABRIELE M		22,500	$1.45	$32.6K	SEC filing for CERRONE GABRIELE M (opens in a new tab)
2026-07-21	Mantelli Flavio history of Mantelli Flavio's purchases	Other C-suite	20,000	$1.40	$28.0K	SEC filing for Mantelli Flavio (opens in a new tab)
2026-07-22	Dempsey Robert John history of Dempsey Robert John's purchases	CEO	15,000	$1.54	$23.1K	SEC filing for Dempsey Robert John (opens in a new tab)
2026-07-21	BRANCACCIO JOHN P history of BRANCACCIO JOHN P's purchases	Director	5,000	$1.48	$7.4K	SEC filing for BRANCACCIO JOHN P (opens in a new tab)
2026-07-27	Patil Rajkumar V. history of Patil Rajkumar V.'s purchases	Other C-suite	3,363	$1.49	$5.0K	SEC filing for Patil Rajkumar V. (opens in a new tab)
2026-07-21	JACOB GARY S history of JACOB GARY S's purchases	Other C-suite	3,500	$1.40	$4.9K	SEC filing for JACOB GARY S (opens in a new tab)
Total					$136.0K

What happened next

A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.

After this run became a cluster: 21 days -3.2%63 days –126 days –